Bharat Biotech urges Centre to incorporate its intranasal covid vaccine in CoWIN portal
3 min readBy PTI
HYDERABAD: Bharat Biotech has requested the central authorities to incorporate its intranasal covid-19 vaccine iNCOVACC, in CoWIN portal to allow the recipients of the jab to get vaccination certificates.
The firm sources stated Bharat Biotech is presently holding discussions with worldwide ‘potential companions’ who’ve approached the corporate for manufacturing and distribution of the intranasal vaccine globally.
“Since iNCOVACC has been approved for “Restricted use underneath emergency scenario” and vaccine recipients will require vaccine certificates, we have requested the government to include iNCOVACC in the COWIN portal. Once this is enabled, India will be one of the few countries to have introduced an intranasal vaccine in its immunization program against COVID,” the sources informed PTI.
Currently Bharat Biotech’s Covaxin, Serum Institute’s Covishield and Covovax, Russian Sputink V and Biological E Ltd’s Corbevax are listed within the CoWin portal.
The vaccine maker on September 6 introduced that its iNCOVACC (BBV154), world’s first intranasal COVID-19 vaccine has obtained approval from Drugs Controller General of India underneath Restricted Use in Emergency Situation for ages 18 and above.
“There have been no requests for procurement from state or central governments,” sources additional stated.
The city-based vaccine maker additionally plans to export iNCOVACC to different international locations as soon as it will get approvals from the respective nations, sources added.
iNCOVACC (BBV154) has additionally obtained approval from the Central Drugs Standard Control Organisation (CDSCO) underneath Restricted Use in Emergency Situation for ages 18 and above in India, for heterologous booster doses.
The vaccine was developed in partnership with Washington University, St Louis, which had designed and developed the recombinant adenoviral vectored assemble and evaluated in pre-clinical research for efficacy.
The vaccine candidate underwent Phases I, II and III scientific trials with profitable outcomes and has been particularly formulated to permit intranasal supply by way of nasal drops.
Phase-III trials have been carried out for security, immunogenicity in roughly 3,100 topics, at 14 trial websites throughout India.
HYDERABAD: Bharat Biotech has requested the central authorities to incorporate its intranasal covid-19 vaccine iNCOVACC, in CoWIN portal to allow the recipients of the jab to get vaccination certificates.
The firm sources stated Bharat Biotech is presently holding discussions with worldwide ‘potential companions’ who’ve approached the corporate for manufacturing and distribution of the intranasal vaccine globally.
“Since iNCOVACC has been approved for “Restricted use underneath emergency scenario” and vaccine recipients will require vaccine certificates, we have requested the government to include iNCOVACC in the COWIN portal. Once this is enabled, India will be one of the few countries to have introduced an intranasal vaccine in its immunization program against COVID,” the sources informed PTI.
Currently Bharat Biotech’s Covaxin, Serum Institute’s Covishield and Covovax, Russian Sputink V and Biological E Ltd’s Corbevax are listed within the CoWin portal.
The vaccine maker on September 6 introduced that its iNCOVACC (BBV154), world’s first intranasal COVID-19 vaccine has obtained approval from Drugs Controller General of India underneath Restricted Use in Emergency Situation for ages 18 and above.
“There have been no requests for procurement from state or central governments,” sources additional stated.
The city-based vaccine maker additionally plans to export iNCOVACC to different international locations as soon as it will get approvals from the respective nations, sources added.
iNCOVACC (BBV154) has additionally obtained approval from the Central Drugs Standard Control Organisation (CDSCO) underneath Restricted Use in Emergency Situation for ages 18 and above in India, for heterologous booster doses.
The vaccine was developed in partnership with Washington University, St Louis, which had designed and developed the recombinant adenoviral vectored assemble and evaluated in pre-clinical research for efficacy.
The vaccine candidate underwent Phases I, II and III scientific trials with profitable outcomes and has been particularly formulated to permit intranasal supply by way of nasal drops.
Phase-III trials have been carried out for security, immunogenicity in roughly 3,100 topics, at 14 trial websites throughout India.
